J Korean Matern Child Health .  2024 Oct;28(4):150-152. 10.21896/jkmch.2024.28.4.150.

Computer-Assisted Mental Health Solutions in Depression Treatment

• Kim HS
• Cho GJ

• KMID: 2560349
• DOI: http://doi.org/10.21896/jkmch.2024.28.4.150

Reference

Abd-Alrazaq A., AlSaad R., Aziz S., Ahmed A., Denecke K., Househ M, et al. Wearable artificial intelligence for anxiety and depression: scoping review. J Med Internet. 2023. 25:e42672.

Business Wire. Otsuka and Click Therapeutics announce the U.S. Food and Drug Administration (FDA) clearance of Rejoyn ^TM, the first prescription digital therapeutic authorized for the adjunctive treatment of major depressive disorder (MDD) symptoms. [Internet]. Business Wire. 2024. [cited 2024 Apr 1]. Available from: https://www.businesswire.com/news/home/20240401758231/en/.

Choi KM. The AI chatbot platform "SimSimi" is leading the way in depression treatment based on artificial intelligence, in collaboration with Korea University's Anam Hospital. Artificial Intelligence Times [Internet]. Korea. 2022 Sep 28. [cited 2024 May 9]. Available from: https://www.aitimes.kr/news/articleView.html?idxno=26115.

Fitzpatrick KK., Darcy A., Vierhile M. Delivering cognitive behavior therapy to young adults with symptoms of depression and anxiety using a fully automated conversational agent (Woebot): a randomized controlled trial. JMIR Ment Health. 2017. 4:e19.

Fu G., Yu Y., Ye J., Zheng Y., Li W., Cui N, et al. A method for diagnosing depression: Facial expression mimicry is evaluated by facial expression recognition. J Affect Disord. 2023. 323:809–18.

Gaffney H., Mansell W., Tai S. Conversational agents in the treatment of mental health problems: mixed-method systematic review. JMIR Ment Health. 2019. 6:e14166.

Kaywan P., Ahmed K., Ibaida A., Miao Y., Gu B. Early detection of depression using a conversational AI bot: a non-clinical trial. PLoS One. 2023. 18:e0279743.

Health Information Science: 10th International Conference, HIS 2021, Melbourne, VIC, Australia, October 25–28, 2021, Proceedings. 193–204. https://doi.org/10.1007/978-3-030-90885-0_18.

Miura Y., Ogawa Y., Shibata A., Kamijo K., Joko K., Aoki T. App-based interventions for the prevention of postpartum depression: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2023. 23:441.

Pawlowski MA., Gazea M., Wollweber B., Dresler M., Holsboer F., Keck ME, et al. Heart rate variability and cordance in rapid eye move-ment sleep as biomarkers of depression and treatment response. J Psychiatr Res. 2017. 92:64–73.

Pokhrel P., Rath S., Aggarwal R., Shah ST., Ahmadi L. Enhancing mental wellness: a reflection on Rejoyn app's FDA approval for depression management. Asian J Psychiatr. 2024. 99:104147.

Suharwardy S., Ramachandran M., Leonard SA., Gunaseelan A., Lyell DJ., Darcy A, et al. Feasibility and impact of a mental health chatbot on postpartum mental health: a randomized controlled trial. AJOG Glob Rep. 2023. 3:100165.

Xu R., Hua A., Wang A., Lin Y. Early depression detection for young adults with a psychiatric and AI interdisciplinary multimodal frame-work. Int J Psychol Behav Sci. 2021. 15:219–25.

Woebot Health. Scalable Enterprise Solution for Mental Health [Internet]. USA; [cited 2024 Jul 15]. Available from: https://www.WoebotHealth.com.

World Laws Information Center. The European Parliament has passed the "AI Act." [Internet]. Sejong (Korea): Korea Ministry of Government Legislation;2024. [cited 2024 May 9]. Available from: https://world.moleg.go.kr/web/dta/lgslTrendReadPage.do?A=A&searchType=all&searchPageRowCnt=10&CTS_SEQ=52117&AST_ SEQ=96&ETC=1.

Wright JH., Owen JJ., Richards D., Eells TD., Richardson T., Brown GK, et al. Computer-assisted cognitive-behavior therapy for depression: a systematic review and meta-analysis. J Clin Psychiatry. 2019. 80:18r12188.